Analysts Set Expectations for RIGL Q1 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for shares of Rigel Pharmaceuticals in a research note issued on Wednesday, March 5th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings per share of ($0.07) for the quarter. HC Wainwright has a “Buy” rating and a $57.00 price target on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ Q2 2025 earnings at $0.12 EPS, FY2025 earnings at $0.88 EPS and FY2026 earnings at $2.08 EPS.

RIGL has been the subject of a number of other reports. Cantor Fitzgerald increased their price target on shares of Rigel Pharmaceuticals from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Tuesday, December 10th. Citigroup upped their price objective on shares of Rigel Pharmaceuticals from $49.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday. Piper Sandler lifted their target price on Rigel Pharmaceuticals from $15.00 to $23.00 and gave the stock a “neutral” rating in a research report on Thursday, November 14th. StockNews.com cut Rigel Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. Finally, B. Riley lifted their price objective on Rigel Pharmaceuticals from $20.00 to $24.00 and gave the stock a “neutral” rating in a report on Wednesday. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $36.80.

Rigel Pharmaceuticals Trading Down 2.9 %

RIGL opened at $19.70 on Friday. The business has a 50 day moving average of $20.09 and a 200-day moving average of $18.42. The stock has a market capitalization of $347.02 million, a price-to-earnings ratio of 140.72 and a beta of 1.35. Rigel Pharmaceuticals has a 1-year low of $7.48 and a 1-year high of $29.82.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its earnings results on Tuesday, March 4th. The biotechnology company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.50. The firm had revenue of $57.60 million during the quarter, compared to the consensus estimate of $57.59 million. Rigel Pharmaceuticals had a negative return on equity of 14.80% and a net margin of 2.46%.

Insider Buying and Selling

In other news, EVP David A. Santos sold 2,125 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $20.92, for a total value of $44,455.00. Following the completion of the transaction, the executive vice president now directly owns 53,500 shares of the company’s stock, valued at approximately $1,119,220. This represents a 3.82 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Raul R. Rodriguez sold 4,952 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $20.92, for a total value of $103,595.84. Following the transaction, the chief executive officer now owns 243,854 shares of the company’s stock, valued at $5,101,425.68. This trade represents a 1.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 9,113 shares of company stock valued at $190,644 over the last quarter. Corporate insiders own 9.04% of the company’s stock.

Institutional Investors Weigh In On Rigel Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Rigel Pharmaceuticals during the 4th quarter valued at about $676,000. Soleus Capital Management L.P. increased its holdings in shares of Rigel Pharmaceuticals by 21.0% during the fourth quarter. Soleus Capital Management L.P. now owns 1,130,679 shares of the biotechnology company’s stock worth $19,018,000 after buying an additional 195,891 shares in the last quarter. Squarepoint Ops LLC raised its stake in shares of Rigel Pharmaceuticals by 40.1% in the fourth quarter. Squarepoint Ops LLC now owns 63,416 shares of the biotechnology company’s stock valued at $1,067,000 after acquiring an additional 18,159 shares during the last quarter. Two Sigma Advisers LP boosted its holdings in shares of Rigel Pharmaceuticals by 63.0% in the 4th quarter. Two Sigma Advisers LP now owns 63,128 shares of the biotechnology company’s stock worth $1,062,000 after acquiring an additional 24,400 shares in the last quarter. Finally, Two Sigma Investments LP bought a new stake in Rigel Pharmaceuticals during the 4th quarter worth approximately $1,025,000. Institutional investors and hedge funds own 66.23% of the company’s stock.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.